Opko Health Inc

Stock Chart, Company Information, and Scan Results

$1.51(as of Sep 18, 3:59 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Opko Health Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$1.51
Ticker SymbolOPK
ExchangeNasdaq
SectorHealthcare
IndustryDiagnostics & Research
Employees2,997
CountyUSA
Market Cap$1,103.4M
EBIDTA-172.8M
10-Day Moving Average1.41
P/E Ratio-5.72
20-Day Moving Average1.40
Forward P/E Ratio64.52
50-Day Moving Average1.36
Earnings per Share-0.26
200-Day Moving Average1.47
Profit Margin-94.66%
RSI66.71
Shares Outstanding793.8M
ATR0.05
52-Week High2.04
Volume3,592,393
52-Week Low1.11
Most Recent Support Level1.34
Book Value1,296.9M
Most Recent Resistance Level1.44
P/B Ratio0.78
Upper Keltner1.51
P/S Ratio1.53
Lower Keltner1.29
Debt-to-Equity Ratio1.51
Next Earnings Date11/05/2025
Cash Surplus100.5M
Next Ex-Dividend DateUnknown

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offer laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, immunology, and infectious diseases; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins or peptides; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products for a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. OPKO Health, Inc. was founded in 2007 and is headquartered in Miami, Florida.

Opko Health Inc In Our Stock Scanner

As of Sep 19, 2025
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Momentum StocksScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Low PS RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.